Click on image to view larger version.

Figure 1 Event-free survival according to the dobutamine technetium-99m-sestamibi single-photon emission computed tomography (SPECT) results. Event-free survival is significantly better in patients with normal SPECT results than it is in those with abnormal SPECT results. The curves begin to diverge early, with relatively few cardiac events during the first year of follow-up in patients with normal SPECT results.